Mirum Pharmaceuticals, Inc. Payments to Acquire Investments
Mirum Pharmaceuticals, Inc. (MIRM) reported Payments to Acquire Investments of $195.61 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-08-05
- Mirum Pharmaceuticals, Inc. payments to acquire investments for the quarter ending 2026-06-30 was $160.81M, a 409.92% increase year-over-year.
- Mirum Pharmaceuticals, Inc. payments to acquire investments for the quarter ending 2026-03-31 was $34.80M, a 3.79% increase year-over-year.
- Mirum Pharmaceuticals, Inc. payments to acquire investments for the quarter ending 2025-12-31 was $11.50M, a 0.17% increase year-over-year.
- Mirum Pharmaceuticals, Inc. payments to acquire investments for the quarter ending 2025-09-30 was $20.86M, a 33.68% increase year-over-year.
- Mirum Pharmaceuticals, Inc. payments to acquire investments for fiscal 2025 was $97.42M, a 9.43% increase from fiscal 2024.
- Mirum Pharmaceuticals, Inc. payments to acquire investments for fiscal 2024 was $89.03M, a 225.76% increase from fiscal 2023.
- Mirum Pharmaceuticals, Inc. payments to acquire investments for fiscal 2023 was $27.33M, a 79.35% decline from fiscal 2022.
- Mirum Pharmaceuticals, Inc. payments to acquire investments for fiscal 2022 was $132.32M, a 33.18% decline from fiscal 2021.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 8 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $160.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $195.61M 10-Q · filed 2026-08-05 | $207.11M derived: sum of 3 quarters · filed 2026-08-05 | $227.97M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $34.80M 10-Q · filed 2026-05-06 | $46.30M derived: sum of 2 quarters · filed 2026-05-06 | $67.16M derived: sum of 3 quarters · filed 2026-05-06 | $98.70M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $11.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $32.36M derived: sum of 2 quarters · filed 2026-02-25 | $63.90M derived: sum of 3 quarters · filed 2026-08-05 | $97.42M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $20.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $52.40M derived: sum of 2 quarters · filed 2026-08-05 | $85.92M 10-Q · filed 2025-11-04 | $97.41M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $31.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $65.06M 10-Q · filed 2026-08-05 | $76.55M derived: sum of 3 quarters · filed 2026-08-05 | $92.15M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $33.53M 10-Q · filed 2026-05-06 | $45.01M derived: sum of 2 quarters · filed 2026-05-06 | $60.61M derived: sum of 3 quarters · filed 2026-05-06 | $122.55M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $11.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $27.09M derived: sum of 2 quarters · filed 2026-02-25 | $89.03M derived: sum of 3 quarters · filed 2026-02-25 | $89.03M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $15.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $77.54M derived: sum of 2 quarters · filed 2025-11-04 | $77.54M 10-Q · filed 2025-11-04 | $77.54M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-06-30 | $61.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $61.94M 10-Q · filed 2025-08-06 | $61.94M derived: sum of 3 quarters · filed 2026-02-25 | $61.94M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $4.88M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $4.88M derived: sum of 3 quarters · filed 2026-02-25 | $27.33M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $4.88M derived: sum of 2 quarters · filed 2024-11-12 | $27.33M 10-Q · filed 2024-11-12 | $27.33M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-06-30 | $4.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $27.33M 10-Q · filed 2024-08-07 | $27.33M derived: sum of 3 quarters · filed 2025-02-26 | $144.84M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-03-31 | $22.44M 10-Q · filed 2024-05-08 | $22.44M derived: sum of 2 quarters · filed 2025-02-26 | $139.95M derived: sum of 3 quarters · filed 2025-02-26 | $154.77M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $117.51M derived: sum of 2 quarters · filed 2025-02-26 | $132.32M derived: sum of 3 quarters · filed 2025-02-26 | $132.32M 10-K · filed 2025-02-26 | |
| 2022-09-30 | $117.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $132.32M derived: sum of 2 quarters · filed 2023-11-02 | $132.32M 10-Q · filed 2023-11-02 | $151.30M derived: sum of 4 quarters · filed 2024-03-15 | |
| 2022-06-30 | $14.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $14.81M 10-Q · filed 2023-08-07 | $33.79M derived: sum of 3 quarters · filed 2024-03-15 | $83.50M derived: sum of 4 quarters · filed 2024-03-15 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-04 | $18.97M derived: sum of 2 quarters · filed 2024-03-15 | $68.69M derived: sum of 3 quarters · filed 2024-03-15 | $114.65M derived: sum of 4 quarters · filed 2024-03-15 | |
| 2021-12-31 | $18.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $68.69M derived: sum of 2 quarters · filed 2024-03-15 | $114.65M derived: sum of 3 quarters · filed 2024-03-15 | $198.03M 10-K · filed 2024-03-15 | |
| 2021-09-30 | $49.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $95.67M derived: sum of 2 quarters · filed 2022-11-09 | $179.06M 10-Q · filed 2022-11-09 | $201.63M derived: sum of 4 quarters · filed 2022-11-09 | |
| 2021-06-30 | $45.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $129.34M 10-Q · filed 2022-08-04 | $151.91M derived: sum of 3 quarters · filed 2022-08-04 | $189.88M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | $83.38M 10-Q · filed 2022-05-05 | $105.95M derived: sum of 2 quarters · filed 2022-05-05 | $143.92M derived: sum of 3 quarters · filed 2022-05-05 | $157.94M derived: sum of 4 quarters · filed 2022-05-05 | |
| 2020-12-31 | $22.57M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | $60.54M derived: sum of 2 quarters · filed 2022-03-09 | $74.56M derived: sum of 3 quarters · filed 2022-03-09 | $74.56M 10-K · filed 2022-03-09 | |
| 2020-09-30 | $37.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $51.99M derived: sum of 2 quarters · filed 2021-11-15 | $51.99M 10-Q · filed 2021-11-15 | $73.07M derived: sum of 4 quarters · filed 2021-11-15 | |
| 2020-06-30 | $14.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $14.02M 10-Q · filed 2021-08-05 | $35.10M derived: sum of 3 quarters · filed 2021-08-05 | $107.62M derived: sum of 4 quarters · filed 2021-08-05 | |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-06 | $21.08M derived: sum of 2 quarters · filed 2021-05-06 | $93.60M derived: sum of 3 quarters · filed 2021-05-06 | ||
| 2019-12-31 | $21.08M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $93.60M derived: sum of 2 quarters · filed 2021-03-09 | $152.00M 10-K · filed 2021-03-09 | ||
| 2019-09-30 | $72.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $130.92M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | $58.40M 10-Q · filed 2020-08-06 | ||||
| 2018-12-31 | $0.00 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |